AN OPEN-LABEL TRIAL OF THE PPAR-γ LIGAND PIOGLITAZONE FOR IDIOPATHIC GASTROPARESIS: A FIRST STEP TOWARDS DISEASE MODIFYING THERAPY

Authors
Category Primary study
JournalGastroenterology
Year 2022
This article has no abstract
Epistemonikos ID: c91c8d7af49f4d707a8c6331356621400935b5ef
First added on: Feb 14, 2025